(NASDAQ:AEMD) SAN DIEGO, Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an...
Related Questions
How will the $4.5âŻmillion public offering affect Aethlonâs cash runway and future financing needs?
What pricing terms (e.g., discount to market, lockâup period) were set for the offering, and how might they impact existing shareholders?
Will the use of proceedsâas outlined by managementâenhance the companyâs drug pipeline and potentially drive future earnings growth?